Search clinical trials for: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal

Total 21 results

Merck Sharp & Dohme LLC

Completed

A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Shingles
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

Herpes Zoster | Shingles
Merck Sharp & Dohme LLC

Completed

ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

Herpes Zoster | Shingles
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

Herpes Zoster | Shingles
Merck Sharp & Dohme LLC
University of Colorado, Denver; Duke University

Completed

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

Herpes Zoster | Varicella-zoster Vaccine
Merck Sharp & Dohme LLC
Kaiser Permanente

Completed

ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)

Herpes Zoster | Shingles
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020

Herpes Zoster

United States
HaEmek Medical Center, Israel

Unknown

Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients

Herpes Zoster

Israel
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination

Hepatitis C

United States
University of Washington
Merck Sharp & Dohme LLC

Completed

Immune Response to Shingles Vaccination

Shingles

United States
University of Alberta

Completed

Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation

Kidney Transplant

Canada
Merck Sharp & Dohme LLC

Completed

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

Herpes Zoster | Pneumococcal Infection
Merck Sharp & Dohme LLC

Completed

ZOSTAVAX(R) Local Registration Trial (V211-019)

Varicella Virus Infection
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

Prevention of : Herpes-Zoster
University of Toronto
Canadian Institutes of Health Research (CIHR); University of Nairobi; Kenyan...

Unknown

Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine (KAVI-VZV-001)

Healthy

Kenya
Tulane University

Completed

Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™

Fibrosis | Herpes Zoster
Louis Stokes VA Medical Center
Duke University

Unknown

ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors

Shingles
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection

3

Subscribe